ArticleBritish journal of cancer2017

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.

L M Schiffmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.